RE: Crazy cheapToday 10:31
Smart buyers realising what the potential is here now.
- Cashed up
- on track to meet market expectations for year.
- Part of game changing consortium which CEO described at transformational for company’s prospects and gave them equivalent of free £6m raise.
- USA national cancer institute validating their flagship tech which is propietary, patent pending and has potential to change the market.
- validation project nearing conclusion of 2 years and generating results and they now have the cash to complete and commercialise.
Yet the MCAP is sitting here - madness - “ This
ascribes almost no value to Fusion’s leading antibody discovery technologies, and hence
we suggest the shares to offer a return geared to the company’s financial recovery.”
“ In our view, Fusion is clearly undervalued compared with its peers.
When balanced with FairJourney and its recent €900m valuation, FAB’s current
market capitalisation of £4.2m reflects neither the investment made nor the
technology. We believe that the market has not yet accounted for the current recovery
in sales and orderbook, or for the potential of the new proprietary platforms
(OptiMAL®, OptiPhage™ and AI/ML-Ab™). This is just a matter of time, and the current
interim results trading statement presents FAB with a much improved outlook and
stronger bases”